Overview

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Criteria
Inclusion Criteria:

- Hypercholesterolemia

- Currently taking a stable daily dose of statin therapy

- Serum triglyceride level < 500mg/dl

Exclusion Criteria:

- History of myocardial infarction, coronary angioplasty or bypass grafts, valvular
disease or repair, unstable angina pectoris, transient ischemic attack, or
cerebrovascular accidents within six months prior to entry into the study

- Congestive heart failure

- Diabetes mellitus

- Active liver disease

- Impaired renal function

- Hepatitis C, B and HIV

This list is not inclusive; additional information is provided in the protocol